Valisure Participation in Virtual Summit on Safe, Effective, & Accessible High-Quality Medicines

Valisure is honored to collaborate with leading healthcare organizations including the American Hospital Association (AHA), American Medical Association (AMA), American Society of Health-System Pharmacists (ASHP), and the United States Pharmacopeia (USP)—all of which play critical roles in advancing the quality, accessibility, and safety of medications in the U.S. healthcare system.

Together, these organizations work to support clinical decision-making, patient communication, and the availability of high-quality pharmaceuticals, reinforcing the importance of transparency and accountability across the drug supply chain.

Highlighting Drug Contamination at the National Level

In July 2020, Valisure Co-Founder & President David Light participated in the Virtual Summit on Safe, Effective, and Accessible High-Quality Medicines as a Matter of National Security, hosted by the AHA, AMA, ASHP, and USP. The summit brought together national experts to address vulnerabilities in the U.S. pharmaceutical supply chain and explore policy and industry recommendations.

David Light presented on drug contamination issues, specifically focusing on the presence of probable human carcinogens NDMA and DMF in valsartan, a commonly used blood pressure medication. These contaminants were found in both generic products and the branded version made by Novartis, underscoring systemic challenges in global drug manufacturing oversight.

Summit Goals and Outcomes

The summit, later summarized in a paper published in the American Journal of Health-System Pharmacy (November 2020), focused on:

  • Strengthening U.S. pharmaceutical supply chain resilience
  • Enhancing regulatory systems both domestically and globally
  • Developing a unified national security and public health strategy
  • Supporting clinical decision-making and effective communication with patients

These efforts reflect a growing consensus that medication quality is not only a clinical priority, but a matter of national security.

Learn More About Our Partners

  • AHA – Advocating for nearly 5,000 hospitals and healthcare systems across the U.S.
  • AMA – The unified voice of over 190 medical societies, focused on eliminating obstacles to care
  • ASHP – Representing over 55,000 pharmacists and pharmacy professionals nationwide
  • USP – Setting science-based quality standards to protect the global medicine supply

Valisure Participation in Virtual Summit on Safe, Effective, & Accessible High-Quality Medicines

November 28, 2020

Valisure is honored to collaborate with leading healthcare organizations including the American Hospital Association (AHA), American Medical Association (AMA), American Society of Health-System Pharmacists (ASHP), and the United States Pharmacopeia (USP)—all of which play critical roles in advancing the quality, accessibility, and safety of medications in the U.S. healthcare system.

Together, these organizations work to support clinical decision-making, patient communication, and the availability of high-quality pharmaceuticals, reinforcing the importance of transparency and accountability across the drug supply chain.

Highlighting Drug Contamination at the National Level

In July 2020, Valisure Co-Founder & President David Light participated in the Virtual Summit on Safe, Effective, and Accessible High-Quality Medicines as a Matter of National Security, hosted by the AHA, AMA, ASHP, and USP. The summit brought together national experts to address vulnerabilities in the U.S. pharmaceutical supply chain and explore policy and industry recommendations.

David Light presented on drug contamination issues, specifically focusing on the presence of probable human carcinogens NDMA and DMF in valsartan, a commonly used blood pressure medication. These contaminants were found in both generic products and the branded version made by Novartis, underscoring systemic challenges in global drug manufacturing oversight.

Summit Goals and Outcomes

The summit, later summarized in a paper published in the American Journal of Health-System Pharmacy (November 2020), focused on:

  • Strengthening U.S. pharmaceutical supply chain resilience
  • Enhancing regulatory systems both domestically and globally
  • Developing a unified national security and public health strategy
  • Supporting clinical decision-making and effective communication with patients

These efforts reflect a growing consensus that medication quality is not only a clinical priority, but a matter of national security.

Learn More About Our Partners

  • AHA – Advocating for nearly 5,000 hospitals and healthcare systems across the U.S.
  • AMA – The unified voice of over 190 medical societies, focused on eliminating obstacles to care
  • ASHP – Representing over 55,000 pharmacists and pharmacy professionals nationwide
  • USP – Setting science-based quality standards to protect the global medicine supply

Valisure Participation in Virtual Summit on Safe, Effective, & Accessible High-Quality Medicines

Valisure is honored to collaborate with leading healthcare organizations including the American Hospital Association (AHA), American Medical Association (AMA), American Society of Health-System Pharmacists (ASHP), and the United States Pharmacopeia (USP)—all of which play critical roles in advancing the quality, accessibility, and safety of medications in the U.S. healthcare system.

Together, these organizations work to support clinical decision-making, patient communication, and the availability of high-quality pharmaceuticals, reinforcing the importance of transparency and accountability across the drug supply chain.

Highlighting Drug Contamination at the National Level

In July 2020, Valisure Co-Founder & President David Light participated in the Virtual Summit on Safe, Effective, and Accessible High-Quality Medicines as a Matter of National Security, hosted by the AHA, AMA, ASHP, and USP. The summit brought together national experts to address vulnerabilities in the U.S. pharmaceutical supply chain and explore policy and industry recommendations.

David Light presented on drug contamination issues, specifically focusing on the presence of probable human carcinogens NDMA and DMF in valsartan, a commonly used blood pressure medication. These contaminants were found in both generic products and the branded version made by Novartis, underscoring systemic challenges in global drug manufacturing oversight.

Summit Goals and Outcomes

The summit, later summarized in a paper published in the American Journal of Health-System Pharmacy (November 2020), focused on:

  • Strengthening U.S. pharmaceutical supply chain resilience
  • Enhancing regulatory systems both domestically and globally
  • Developing a unified national security and public health strategy
  • Supporting clinical decision-making and effective communication with patients

These efforts reflect a growing consensus that medication quality is not only a clinical priority, but a matter of national security.

Learn More About Our Partners

  • AHA – Advocating for nearly 5,000 hospitals and healthcare systems across the U.S.
  • AMA – The unified voice of over 190 medical societies, focused on eliminating obstacles to care
  • ASHP – Representing over 55,000 pharmacists and pharmacy professionals nationwide
  • USP – Setting science-based quality standards to protect the global medicine supply

Valisure is honored to collaborate with leading healthcare organizations including the American Hospital Association (AHA), American Medical Association (AMA), American Society of Health-System Pharmacists (ASHP), and the United States Pharmacopeia (USP)—all of which play critical roles in advancing the quality, accessibility, and safety of medications in the U.S. healthcare system.

Together, these organizations work to support clinical decision-making, patient communication, and the availability of high-quality pharmaceuticals, reinforcing the importance of transparency and accountability across the drug supply chain.

Highlighting Drug Contamination at the National Level

In July 2020, Valisure Co-Founder & President David Light participated in the Virtual Summit on Safe, Effective, and Accessible High-Quality Medicines as a Matter of National Security, hosted by the AHA, AMA, ASHP, and USP. The summit brought together national experts to address vulnerabilities in the U.S. pharmaceutical supply chain and explore policy and industry recommendations.

David Light presented on drug contamination issues, specifically focusing on the presence of probable human carcinogens NDMA and DMF in valsartan, a commonly used blood pressure medication. These contaminants were found in both generic products and the branded version made by Novartis, underscoring systemic challenges in global drug manufacturing oversight.

Summit Goals and Outcomes

The summit, later summarized in a paper published in the American Journal of Health-System Pharmacy (November 2020), focused on:

  • Strengthening U.S. pharmaceutical supply chain resilience
  • Enhancing regulatory systems both domestically and globally
  • Developing a unified national security and public health strategy
  • Supporting clinical decision-making and effective communication with patients

These efforts reflect a growing consensus that medication quality is not only a clinical priority, but a matter of national security.

Learn More About Our Partners

  • AHA – Advocating for nearly 5,000 hospitals and healthcare systems across the U.S.
  • AMA – The unified voice of over 190 medical societies, focused on eliminating obstacles to care
  • ASHP – Representing over 55,000 pharmacists and pharmacy professionals nationwide
  • USP – Setting science-based quality standards to protect the global medicine supply